Literature DB >> 7904591

Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells.

V Stefanovic1, N Ardaillou, P Vlahovic, S Placier, P Ronco, R Ardaillou.   

Abstract

Because dipeptidylpeptidase IV (DPP IV) is present in vivo on glomerular visceral epithelial cells and possesses immunogenic properties, as shown by the capability of anti-DPP IV antibody to induce the Heymann model of glomerulonephritis, we studied the expression and regulation of DPP IV in cultured human glomerular visceral epithelial cells. DPP IV is an ectoenzyme, as indicated by the rapid detection of the product of the reaction in the incubation medium of intact cells and the staining of paraformaldehyde-fixed cells in the presence of a specific anti-DPP IV antibody. DPP IV activity was inhibited by diisopropylfluorophosphate and phenylmethyl sulphonylfluoride. Its optimum pH was alkaline (7.7-8) and it exhibited a Km value of 0.94 mM. DPP IV expression was induced in cells treated by interferon-gamma (IFN-gamma). The effect was significant after a 3-day treatment with 100 U/ml. It increased with time, reaching a plateau after 11 days, and was dose-dependent with a maximum at a concentration of 1000 U/ml. Staining of the cells with anti-DPP IV antibody was also increased after a 6-day treatment with 100 U/ml IFN-gamma. It was shown by Northern analysis that, after 24 hr of exposure to 500 U/ml of IFN-gamma, DPP IV mRNA transcript was stimulated. Transcriptional activation by IFN-gamma did not require new protein synthesis. Interleukin-1 (IL-1) and cyclic AMP had a small stimulatory effect, whereas dexamethasone and phorbol esters were inefficient. These results suggest that DPP IV of glomerular epithelial cells may be up-regulated by IFN-gamma from activated T lymphocytes in glomerular diseases and during lymphocyte-mediated graft rejection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904591      PMCID: PMC1422210     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: preferential expression by immature CD4-CD8- subpopulation.

Authors:  B Bauvois
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

2.  Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro.

Authors:  H Ishikura; C Takahashi; K Kanagawa; H Hirata; K Imai; T Yoshiki
Journal:  Transplantation       Date:  1991-06       Impact factor: 4.939

3.  Antigen processing and presentation by glomerular visceral epithelium in vitro.

Authors:  D L Mendrick; D M Kelly; H G Rennke
Journal:  Kidney Int       Date:  1991-01       Impact factor: 10.612

4.  Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells.

Authors:  G P Dupont; T P Huecksteadt; B C Marshall; U S Ryan; J R Michael; J R Hoidal
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  Urinary excretion of dipeptidyl aminopeptidase i.v. in patients with renal diseases.

Authors:  G Wolf; J E Scherberich; A Nowack; O Stein; W Schoeppe
Journal:  Clin Nephrol       Date:  1990-03       Impact factor: 0.975

6.  Renal allograft rejection: investigation of alloantigen presentation by cultured human renal epithelial cells.

Authors:  J A Kirby; S Ikuta; K Clark; G Proud; T W Lennard; R M Taylor
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

7.  Isolation of a cDNA probe for the human intestinal dipeptidylpeptidase IV and assignment of the gene locus DPP4 to chromosome 2.

Authors:  D Darmoul; M Lacasa; I Chantret; D M Swallow; G Trugnan
Journal:  Ann Hum Genet       Date:  1990-07       Impact factor: 1.670

8.  CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7.

Authors:  A J Ulmer; T Mattern; A C Feller; E Heymann; H D Flad
Journal:  Scand J Immunol       Date:  1990-04       Impact factor: 3.487

9.  Purification and properties of dipeptidyl peptidase IV from human urine.

Authors:  T Chikuma; T Hama; T Nagatsu; M Kumegawa; T Kato
Journal:  Biol Chem Hoppe Seyler       Date:  1990-04

10.  Polarized membrane expression of brush-border hydrolases in primary cultures of kidney proximal tubular cells depends on cell differentiation and is induced by dexamethasone.

Authors:  P Ronco; M Antoine; B Baudouin; M Geniteau-Legendre; B Lelongt; F Chatelet; P Verroust; A Vandewalle
Journal:  J Cell Physiol       Date:  1990-11       Impact factor: 6.384

View more
  18 in total

1.  Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators.

Authors:  A Kehlen; B Göhring; J Langner; D Riemann
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

2.  Discrimination of agonist and antagonist forms of CXCL10 in biological samples.

Authors:  A Casrouge; A Bisiaux; L Stephen; M Schmolz; J Mapes; C Pfister; S Pol; V Mallet; M L Albert
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.

Authors:  Jee Eun Lee; Jung Eun Kim; Mi Hwa Lee; Hye Kyoung Song; Jung Yeon Ghee; Young Sun Kang; Hye Sook Min; Hyun Wook Kim; Jin Joo Cha; Jee Young Han; Sang Youb Han; Dae Ryong Cha
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

Review 4.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

5.  Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.

Authors:  Gianluca Miglio; Giovanna Vitarelli; Thomas Klein; Elisa Benetti
Journal:  Br J Pharmacol       Date:  2017-03-06       Impact factor: 8.739

6.  Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.

Authors:  D Riemann; A Kehlen; J Langner
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

Review 7.  Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure.

Authors:  Thiago A Salles; Leonardo dos Santos; Valério G Barauna; Adriana C C Girardi
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

8.  Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.

Authors:  Grazia Esposito; Donato Cappetta; Rosa Russo; Alessia Rivellino; Loreta Pia Ciuffreda; Fiorentina Roviezzo; Elena Piegari; Liberato Berrino; Francesco Rossi; Antonella De Angelis; Konrad Urbanek
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

9.  Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.

Authors:  Elena Ceccarelli; Elisa G Guarino; Daniela Merlotti; Aurora Patti; Luigi Gennari; Ranuccio Nuti; Francesco Dotta
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-18       Impact factor: 5.555

10.  Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome.

Authors:  Valérie Turcot; André Tchernof; Yves Deshaies; Louis Pérusse; Alexandre Bélisle; Picard Marceau; Frédéric-Simon Hould; Stéfane Lebel; Marie-Claude Vohl
Journal:  Diabetol Metab Syndr       Date:  2013-02-04       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.